Halozyme Therapeutics COO Sells $599,000 in Shares

Cortney Caudill, the Chief Operating Officer, reduced her stake in the biopharmaceutical company by over 55%.

Published on Mar. 11, 2026

Got story updates? Submit your updates here. ›

Halozyme Therapeutics, Inc. (NASDAQ:HALO) COO Cortney Caudill sold 8,857 shares of the company's stock on March 10th, 2026 at an average price of $67.64 per share, resulting in a total transaction of $599,087.48. Following the sale, Caudill now directly owns 7,055 shares in the company valued at $477,200.20.

Why it matters

This transaction represents a significant reduction in Caudill's ownership stake in Halozyme Therapeutics, which could signal a change in her confidence or outlook for the company's future performance. Insider transactions are closely watched by investors as they can provide insights into a company's prospects.

The details

Cortney Caudill, the Chief Operating Officer of Halozyme Therapeutics, sold 8,857 shares of the company's stock on March 10th, 2026. The shares were sold at an average price of $67.64, resulting in a total transaction value of $599,087.48. Following the sale, Caudill now directly owns 7,055 shares in the company, valued at $477,200.20.

  • The share sale transaction occurred on March 10th, 2026.

The players

Cortney Caudill

The Chief Operating Officer of Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc.

A biopharmaceutical company headquartered in San Diego, California that specializes in the development and commercialization of novel drug-delivery technologies.

Got photos? Submit your photos here. ›

The takeaway

This insider transaction by Halozyme's COO could signal a change in her confidence or outlook for the company's future performance, which may be worth monitoring by investors.